Novo Nordisk A/S (NYSE: NVO) has reported E.P.S. of $0.82 for its first fiscal quarter (ending March 31) versus $1.28 for the same period a year ago — a decline of -36%. This result fell short of the consensus estimate of $2.15 by $-1.33. E.P.S. were $2.94 for the latest four quarters through March 31 versus $3.87 for the same period a year ago — a decline of -24%.
Recent Price Action
Novo Nordisk A/S (NYSE: NVO) stock declined by -4.0% on 5/2/24. The shares closed at $124.02. Moreover, trading volume in this decline was unusually high at 177% of normal. The stock has been exceptionally strong relative to the market over the last nine months but has declined -1.7% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, NVO is expected to continue to be a major Value Builder.
Novo Nordisk A/S has a current Value Trend Rating of B (Positive). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Novo Nordisk A/S has a neutral Appreciation Score of 46 but a very high Power Rating of 91, and the Positive Value Trend Rating results.
Rating Review
In light of this new information we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment